Tag: KDC-MN-078

  • MK-677 (Ibutamoren)

    Orally active non-peptide ghrelin receptor agonist

    A Merck-developed orally bioavailable non-peptide ghrelin receptor agonist that produces sustained GH and IGF-1 elevation with once-daily oral dosing.

    Abstract

    MK-677 (Ibutamoren; CAS 159752-10-0; molecular formula C27H36N4O5S; molecular weight 528.66) is a non-peptide ghrelin receptor agonist developed by Merck in the 1990s. Unlike the peptide GHRPs, MK-677 is orally bioavailable and produces sustained GH and IGF-1 elevation over 24 hours with once-daily dosing. Phase 2 trials in elderly subjects showed sustained increases in GH, IGF-1, and lean body mass over 12 to 24 month treatment periods. The compound did not advance to FDA approval; the program was deprioritized after disappointing Phase 3 results in the GHD elderly population. The compound is sold as a research chemical/dietary supplement in some markets, though FDA has issued warnings against its sale as a supplement. Pharmacokinetics: plasma half-life 4 to 6 hours; high oral bioavailability; hepatic CYP3A4 metabolism. Adverse events include increased appetite, water retention, and modest insulin resistance with chronic high-dose use.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.